The 2004 Process of Care: Treatment Options for the Management of Atopic Dermatitis

Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit.

Course Objectives:

This educational monograph is directed towards dermatologists and pediatricians.


Upon the completion of this activity, participants should be able to:

  1. Extensively discuss the efficacy, safety, and tolerability of pharmacologic and non-pharmacologic treatment options for atopic dermatitis in pediatric patients.

  2. Discuss the impact of atopic dermatitis on quality of life and effective strategies for assessment and management.

  3. Establish a consensus on preferred treatment options and best practices for atopic dermatitis.

Accreditation:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of UMDNJ-Center for Continuing and Outreach Education, and Millennium CME Institute, Inc.
UMDNJ-Center for Continuing and Outreach Education is accredited by the ACCME to provide continuing medical education for physicians.



UMDNJ-Center for Continuing and Outreach Education designates this educational activity for a maximum of 1.0 Category 1 Credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.



This activity was prepared in accordance with the ACCME Essentials.



Release Date: September 2004

Expiration Date: December 31, 2005

Faculty Disclosure:

The UMDNJ-Center for Continuing and Outreach Education endorses the Accreditation Council for Continuing Medical Education Standards for Commercial Support. Every effort has been made to encourage faculty to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.




The faculty listed below have declared that they have no financial arrangements or affiliations with any corporate organization offering financial support or grant monies for this CME program or with any corporate organization whose product(s) will be discussed in their presentation(s):

  • Michaeline Daboul
  • Karen Doherty, PharmD
  • David C. Howard
  • Ilyse Lefkowicz, MD
  • Frank P. Murphy, MD
  • Lawrence A. Schachner, MD

The faculty listed below have declared the following arrangements and/or affiliations:

  • Amy S. Paller, MD: Consultant-Fujisawa Healthcare, Inc., Novartis; Speakers Bureau-Fujisawa Healthcare, Inc., Novartis
  • Lawrence Eichenfield, MD: Consultant-Conneticis Corporation, Dermik Laboratories, Fujisawa Healthcare, Inc., Novartis
  • Fred Ghali, MD: Consultant-Fujisawa Healthcare, Inc., Novartis; Speakers Bureau-Fujisawa Healthcare, Inc., Novartis
  • Adelaide Hebert, MD: Grant/Research Support-Berlex, Fujisawa Healthcare, Inc., Galderma, GlaxoSmithKline, Novartis, Pfizer; Consultant-Berlex, Fujisawa Healthcare, Inc., Galderma, GlaxoSmithKline, Novartis, Pfizer; Speakers Bureau-Berlex, Fujisawa Healthcare, Inc., Galderma, GlaxoSmithKline, Novartis, Pfizer
  • George Murakawa, MD, PhD: Speakers Bureau-Novartis

Signed Disclosure forms are on file at the UMDNJ-Center for Continuing
and Outreach Education.



This monograph is not intended as a sole source of treatment options for the management of atopic dermatitis. It has been designed to assist the clinician in evaluating the latest evidence-based medicine and is not intended to replace clinical judgment or establish a protocol for all patients.



This monograph contains information on commercial products that is outside of current approved labeling or information on the investigational use of products not yet approved by the United States Food and Drug Administration. Approved labeling should be consulted prior to treating patients with products discussed herein.

Directions:

The learner should read the learning objectives and study the publication. After analyzing the material, the learner should complete the self-assessment test consisting of a series of multiple-choice questions.



Upon completing this activity as designed, described above, participants will receive a letter of credit awarding AMA/PRA Category 1 Credit six (6) weeks after receipt of the test, registration, and evaluation materials. Registration and evaluation forms will be accepted and credit awarded through December 31, 2005.



Estimated time to complete this activity as designed is 1.0 hour.



This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Frank P. Murphy, MD and Ilyse Lefkowicz, MD.

CME Testing Options